Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA User Fee Hearing Hijacked By US Health Care Reform Arguments

Executive Summary

Democrats argue generic competition alone cannot fix drug pricing problem as senators attempt to pull FDA into Obamacare repeal and replace debate.


Related Content

Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting
Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting
Expanded Access Amendment Could Blunt 'Right To Try' Legislation In US
Senate's User Fee Bill Largely Steers Clear Of Controversy
REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
US Generic Reviews: Would Pre-Submission Meetings Be Better Than Six-Month Priority Review?
REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing
Bill To Speed ANDA Approvals Gets Cool Reception From Industry, US FDA
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
GPhA Pushes REMS Pay-for, Schedule III Hydrocodone In User Fee Bill





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts